The aim was to evaluate the effect of diquafosol on tear film parameters and corneal aberrations after cataract surgery. Methods: This retrospective, comparative, observational case series included patients who underwent cataract surgery with or without peri-operative use of diquafosol three per cent ophthalmic solution. Patients in group I (31 eyes) were treated with diquafosol three per cent ophthalmic solution six times a day from one week before surgery to three months after surgery. Patients in group II (33 eyes) underwent cataract surgery without being administered diquafosol. Tear film break-up time (BUT), the ocular surface disease index (OSDI), the Oxford Scheme score, Schirmer's test I and corneal aberrations were determined before and at one and three months post-surgery. Results: In group I, the BUT, OSDI and Oxford Scheme score showed significant improvement at one and three months post-surgery (p = 0.002 for BUT at one month and three months, p = 0.023 and p = 0.049 for OSDI at one month and three months and p = 0.001 and p = 0.026 for Oxford Scheme at one month and three months), compared to baseline. In group II, the BUT, OSDI and Oxford Scheme score did not show any significant improvement during the follow-up period. In both groups, Schirmer's test I significantly decreased at three months post-surgery (p = 0.011 for group I and p = 0.034 for group II), compared to baseline. There were significant differences in the BUT and OSDI between the groups at three months post-surgery (p = 0.037 for BUT and p = 0.011 for OSDI). Regarding the corneal aberration, there were no significant differences between the groups at three months post-surgery. Conclusion: Peri-operative application of diquafosol three per cent ophthalmic solution may prevent dry eye-related ocular surface changes accompanied by improvement of ocular symptom. No definite changes in corneal aberrations were noted.
Cataract surgery is commonly performed worldwide to restore visual function. Based on improvements in surgical techniques and instruments, the aim of cataract surgery is to bring about improvement in the quality of vision as well as restoration of visual acuity; 1,2 however, a fair number of patients who have undergone cataract surgery has complained of dryness and symptoms of irritation post-operatively. In fact, cataract surgery has been found to exacerbate pre-existing dry eye syndrome and to alter ocular surface conditions even in patients with healthy eyes. 3 There have been several reports of worsening dry eye syndrome after cataract surgery. [4] [5] [6] [7] [8] Generally, dry eye syndrome can be caused by unbalanced tear secretion and evaporation, inflammation of the ocular surface and tear film instability. 9, 10 An altered ocular surface with dry eye after surgery impacts the optical quality significantly, causing a decrease in the quality of vision, as well as ocular surface damage and symptoms of discomfort. 11 If the tear film becomes irregular in thickness, its local irregular anterior radius of curvature and power may induce higher-order aberration changes and decrease in the quality of vision. 12, 13 Artificial tears or lubricating eye drops are often used for tear film restoration and anti-inflammatory agents, such as steroids and cyclosporine A are usually used concurrently for treatment of dry eye syndrome. Many studies have reported that artificial tears improved optical function by reducing corneal or ocular higherorder aberrations as well as improving dry eye symptoms. [14] [15] [16] Diquafosol is a dinucleotide derivative and exhibits purinoreceptor P2Y 2 receptor agonist activity. 17 The P2Y 2 receptor gene is present in conjunctival epithelium including goblet cells, corneal epithelium, meibomian gland and ductal cells on the ocular surface. 18 Diquafosol three per cent ophthalmic solution is known to stimulate not only mucin secretion from goblet cells, but also aqueous secretion from the accessory lacrimal glands in the conjunctiva. 19 Patients who had any other ocular pathologic conditions that might affect visual acuity after cataract surgery, had undergone previous ocular surgery, wore contact lenses, had an active allergic condition, had used topical steroids, cyclosporine A, a non-steroidal anti-inflammatory eye drop or diquafosol three per cent ophthalmic solution (except artificial tears) before cataract surgery or had peri-operative complications including posterior capsular rupture during surgery and prolonged surgery time were excluded. We retrospectively reviewed the medical records of 64 eyes (64 patients) which met the inclusion criteria. Group I (31 eyes) consisted of patients who had used diquafosol three per cent ophthalmic solution six times a day starting from one week prior to cataract surgery to three months after surgery. Group II (33 eyes) consisted of patients who had undergone cataract surgery without using diquafosol three per cent ophthalmic solution, as they had undergone surgery before the launch of this medication in the Korean market.
Surgical technique
All operations were performed by the same surgeon using a temporal clear corneal incision under topical anaesthesia. Initially, one side-port incision and three-step main incision were made and an ophthalmic viscosurgical device (Healon; Abbott Medical Optics Inc., Santa Ana, California, USA) was then injected into the anterior chamber. The Whitestar Signature System (Abbott Medical Optics Inc.) was used for phacoemulsification of nuclear fragments. The intraocular lens (IOL) was selected to achieve emmetropia. After implantation of the targeted IOL, the main incision and the side ports were sealed by stromal hydration using a balanced salt solution (Alcon Laboratories Inc., Fort Worth, Texas, USA). Finally, all wounds were tested for leakage using a cellulose sponge.
After cataract surgery, in all patients, gatifloxacin (Gatiflo; Handok, Seoul, Korea) and one per cent prednisolone acetate (Pred Forte; Allergan Inc, Irvine, California, USA) eye drops were applied four times a day for one month and afterwards; no other medications were used.
Patient examinations
All patients were examined preoperatively and at one and three months post-operatively. Each test was performed in the same order per our pre-set protocol to minimise the extent to which one test influenced the results of the tests that followed. At least five minutes were allowed between tests. The severity of dry eye syndrome was evaluated using the tear film break-up time (BUT), the ocular surface disease index (OSDI), the Oxford Scheme score and Schirmer's test I. To measure BUT, a drop of non-preserved saline solution was added to a fluorescein strip (Haag-Streit, Koeniz, Switzerland) that was applied to the inferior palpebral conjunctiva. The patients were instructed to blink three or four times for a few seconds, then the eye was examined using a slitlamp with maximum cobalt blue light. The physician used a stopwatch to measure the time it took for a single black dot or line to appear on the cornea. The test was performed three times and the results were averaged. 25 Autokeratometry, intraocular pressure measurement with a Goldmann applanation tonometer and slitlamp biomicroscopy were also performed at each visit.
iTrace ray-tracing aberrometer Corneal aberrations were measured using the ray-tracing aberrometer (iTrace; Tracey Technologies, Houston, Texas, USA) at a pupil size of 4.0 mm or more in mesopic conditions, without pharmacologic dilatation. For analysis, data were recalculated for a 4.0-mm pupil using software incorporated into the aberrometer. Corneal aberrations were evaluated preoperatively and at one month and three months post-operatively. In each eye, measurements were taken three times to obtain a well-focused, properly aligned image of the eye and the mean value of those three measurements was used for further analysis. The parameters analysed included Zernike coefficients of the third orders [Z(3,-3) (trefoily), Z(3,-1) (vertical coma), Z(3,1) (horizontal coma), Z(3,3) (trefoil-x)] and fourth orders [Z(4,-4) (tetrafoil), Z(4,0) (spherical aberration), Z(4,4) (tetrafoil)]. The rootmean-square (RMS) values of the total aberration and higher-order aberrations were calculated. RMS value of the higherorder aberrations was analysed up to the fifth order by expanding the set of Zernike polynomials.
Statistical analysis
Data are presented as means and standard deviations. The Kolmogorov-Smirnov test was used to confirm data normality. To statistically compare data between group I and group II, independent t-tests were used for continuous variables and chi-squared tests were used for categorical variables. To evaluate the differences between preoperative and post-operative values for each group, we performed repeated measures analysis of variance (ANOVA) with a Bonferroni-adjusted post hoc comparison. Statistical analysis was performed using SPSS software version 22.0 (IBM, Armonk, NY, USA). Differences were considered statistically significant with p-values less than 0.05.
RESULTS
A total of 64 eyes of 64 patients who underwent cataract surgery with or without perioperative use of diquafosol three per cent ophthalmic solution were ultimately included in analyses. All surgical procedures were uneventful and no postoperative complications were observed during the observation period. Table 1 summarises patient demographic data and ocular surface characteristics before and at one and three months post-surgery. There was no statistically significant difference in sex ratio or age between the groups (Table 1) . In group I, BUT was significantly increased at one and three months after the surgery compared with the preoperative value (p = 0.002, respectively). Both the OSDI and Oxford Scheme score were significantly lower at one and three months after the surgery compared with the preoperative value (p = 0.023 and 0.049 for OSDI and p = 0.001 and 0.026 for Oxford Scheme score, respectively). Schirmer's test I results were significantly lower at three months after the surgery compared with the preoperative value in both groups (p = 0.011 for group I and p = 0.034 for group II, respectively). In group II, the BUT, OSDI and Oxford Scheme score did not show any significant improvement during the follow-up period. Between the groups, at three months after the surgery, the BUT and OSDI were significantly different (p = 0.037 for BUT and p = 0.011 for OSDI, respectively). Table 2 demonstrated the results of preoperative and post-operative corneal aberrations in eyes undergoing cataract surgery with or without peri-operative use of diquafosol three per cent ophthalmic solution. At one month after the surgery, RMS total aberrations and RMS higher-order aberrations showed significant differences between the groups (p = 0.026 for RMS total aberration and p = 0.014 for RMS higher-order aberrations, respectively); however, these changes were neutralised at three months after the surgery, showing no significant differences between the groups ( Table 2 ). In addition, at three months after the surgery, there were no significant differences in all kinds of aberrations between the groups. Repeated measures ANOVA with a Bonferroni-adjusted post hoc comparison demonstrated that there were no significant changes in all kinds of aberrations during the follow-up period in both groups, except the trefoil (Z 3 +3 ) and spherical aberration in group I. Trefoil (Z 3
+3
) significantly increased at three months after the surgery compared with the preoperative value (p = 0.040). Spherical aberration increased at one month after the surgery compared with the preoperative value (p = 0.030), but were eventually neutralised at three months after the surgery.
DISCUSSION
In the present study, we investigated the effect of the use of diquafosol three per cent ophthalmic solution before and after cataract surgery on tear film-associated parameters and corneal aberrations. We found that in the group that used diquafosol three per cent ophthalmic solution, the BUT significantly increased during the follow-up period and the OSDI and Oxford Scheme score significantly decreased postoperatively. In contrast, in the group that did not use diquafosol three per cent ophthalmic solution, no significant changes were found in the BUT, OSDI and Oxford Scheme scores. Interestingly, tear secretion was not affected by the use of diquafosol three per cent ophthalmic solution.
According to a systematic review of randomised clinical trials on the efficacy and safety of topical diquafosol for treatment of dry eye by Wu and colleagues, 26 mucin production evaluated using the BUT showed improvement after diquafosol treatment; however, aqueous tear production measured using Schirmer's test did not demonstrate a consistent improvement. Considering the similar results between that study and our study, we could 
© 2017 Optometry Australia conclude that increased mucin secretion induced by diquafosol plays a major role in increasing tear film stability. The possibility of deterioration in the quality of vision after cataract surgery is associated with the worsening of dry eye symptoms and altered higher-order aberrations. 13 For the measurement of changes in aberrations after cataract surgery, we evaluated corneal aberrations instead of ocular aberrations to avoid the effect of internal aberrations. Based upon our results, at three months after the surgery, there were no significant differences in all kinds of aberrations between the groups. In group I, the spherical aberration increased at one month after the surgery compared with the preoperative value but decreased to the preoperative level at three months after the surgery. Higher-order aberrations were stable three months post-operatively, with the exception of trefoil; however, it might be reasonable to ignore those observed changes in trefoil in the clinical setting. No definite changes in corneal aberrations observed in our study might be attributed to corneal aberrational changes induced by cataract surgical procedures. In fact, we cannot preclude surgical procedure-related corneal aberrational changes for the measurement of changes in corneal aberrations induced by diquafosol after cataract surgery.
Furthermore, one study reported that higher-order aberrations in the posterior and total corneal surfaces were significantly increased at one day after cataract surgery but gradually returned to the baseline values by two months after cataract surgery. 27 In line with that study, we found that in the group that did not use diquafosol three per cent ophthalmic solution, there were no significant differences in corneal aberrations between before and at three months post-surgery.
In patients with aqueous-deficient dry eye, diquafosol treatment demonstrated a significant reduction in higher-order aberrations with improvement in BUT and corneal staining score. 28 This might be mainly due to improvement in punctate keratopathy because of increase in mucin secretion from conjunctival goblet cells induced by diquafosol; 28 however, based upon our results, perioperative diquafosol treatment did not show significant reduction in higher-order aberrations and other corneal aberrations after Table 2 . Changes in corneal aberrations in eyes undergoing cataract surgery with or without peri-operative use of diquafosol three per cent ophthalmic solution Diquafosol after cataract surgery Lee, Kim, Choi, Seo, Kim and Kim cataract surgery. Thus, although diquafosol treatment increases mucin secretion and reduces higher-order aberrations in dry eye, it did not demonstrate any significant changes in corneal aberrations in the setting of cataract surgical procedures, which we assumed resulted in corneal aberrational changes in a different way.
The present study had several limitations, including its retrospective design and relatively short-term follow-up period of three months. Moreover, our study had no control group treated with conventional dry eye treatment, such as sodium hyaluronate. Prospective, randomised, long-term studies evaluating the effects of diquafosol and traditional artificial tears in the setting of cataract surgical procedures would be useful to validate our results.
In conclusion, the preoperative and postoperative use of diquafosol three per cent ophthalmic solution improved ocular surface parameters, such as the BUT and the Oxford Scheme score and ocular symptom score. Therefore, we expect that peri-operative diquafosol treatment can significantly contribute to patient satisfaction after cataract surgery.
